

**Question for written answer E-005386/2021
to the Commission**

Rule 138

Christine Anderson (ID)

Subject: Procedure for selecting vaccines and medicines ordered against COVID-19

The Commission has concluded supply contracts for 4.6 billion vaccine doses with various pharmaceutical companies¹. Alternative products, such as the Russian Sputnik, the Chinese Sinovac or the German LubaVax, scarcely feature, as do such promising medicines as Molnupiravir and Paxlovid².

1. How does the Commission explain its 'vaccination nationalism', whereby people vaccinated abroad are considered unvaccinated in the EU simply because they have not been treated with a Commission product?
2. Why are negotiations not being concluded with promising alternative manufacturers?
3. Why is the vaccination strategy being pursued to the exclusion of all else, with the timely ordering of medicines for treatment neglected – especially where the vaccination strategy is highlighting the need for urgent action due to the high number of breakthrough infections?

¹ https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/public-health/eu-vaccines-strategy_en#documents

² <https://www.augsburger-allgemeine.de/politik/Corona-Pandemie-Noch-keine-Bestellungen-Versagt-Deutschland-bei-der-Corona-Pille-id61155621.html>